The approval of ANKTIVA and its discussion at a significant industry event by a high-profile executive could generate positive buzz around ImmunityBio, enhancing its visibility and potentially leading to increased investor confidence. This scenario typically results in a positive short-term impact on the stock price, assuming the market perceives the approval and the product's market potential favorably.